PD-1 and chemotherapy

DRUG2 trials

Sponsors

Tongji University, Tianjin Medical University Cancer Institute and Hospital

Conditions

ALK Negative NSCLCBiliary Tract Cancer (BTC)EGF-R Negative Non-Small Cell Lung CancerNSCLC, Stage IIIA

Phase 2

Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors

RecruitingNCT07726446

Tianjin Medical University Cancer Institute and HospitalBiliary Tract Cancer (BTC)

Start: 2026-10-01End: 2030-12-01Target: 30Updated: 2026-07-24

Phase 3

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

Tongji UniversityALK Negative NSCLC, EGF-R Negative Non-Small Cell Lung Cancer, NSCLC, Stage IIIA

Start: 2021-10-28End: 2025-10-31Target: 72Updated: 2023-05-09

Related Papers

Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients

Frontiers in Oncology2025-07-24